BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

801 related articles for article (PubMed ID: 9339751)

  • 21. High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma.
    Buser AS; Heim D; Bucher C; Tichelli A; Gratwohl A; Passweg JR
    Bone Marrow Transplant; 2004 May; 33(10):1011-4. PubMed ID: 15064693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Allogeneic transplantation in malignant lymphoma].
    Stötzer OJ; Schleuning M; Ledderose G; Hiddemann W; Kolb HJ
    Dtsch Med Wochenschr; 2001 Sep; 126(39):1062-9. PubMed ID: 11602913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease.
    Hahn T; Benekli M; Wong C; Moysich KB; Hyland A; Michalek AM; Alam A; Baer MR; Bambach B; Czuczman MS; Wetzler M; Becker JL; McCarthy PL
    Bone Marrow Transplant; 2005 Mar; 35(6):557-66. PubMed ID: 15665852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.
    Mandigers CM; Verdonck LF; Meijerink JP; Dekker AW; Schattenberg AV; Raemaekers JM
    Bone Marrow Transplant; 2003 Dec; 32(12):1159-63. PubMed ID: 14647270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K; Margolin K; Champlin R; Forman S
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
    Schiffman K; Buckner CD; Maziarz R; Maloney DG; Appelbaum FR; Press O; Gooley T; Holmberg L; Lilleby K; Clift R; Zuckerman N; Klarnet J; Weaver C; Chauncey T; Bensinger WI
    Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Innsbruck results of bone marrow transplantation in treatment of hematologic neoplasms and solid tumors].
    Nachbaur D; Schwaighofer H; Thaler J; Weyrer W; Fink M; Nussbaumer W; Fritsch E; Niederwieser D
    Wien Klin Wochenschr; 1994; 106(7):201-7. PubMed ID: 8197754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
    Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
    Lazarus HM; Loberiza FR; Zhang MJ; Armitage JO; Ballen KK; Bashey A; Bolwell BJ; Burns LJ; Freytes CO; Gale RP; Gibson J; Herzig RH; LeMaistre CF; Marks D; Mason J; Miller AM; Milone GA; Pavlovsky S; Reece DE; Rizzo JD; van Besien K; Vose JM; Horowitz MM
    Bone Marrow Transplant; 2001 Feb; 27(4):387-96. PubMed ID: 11313668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation.
    Tsai T; Goodman S; Saez R; Schiller G; Adkins D; Callander N; Wolff S; Freytes CO
    Bone Marrow Transplant; 1997 Nov; 20(10):859-63. PubMed ID: 9404927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autologous stem cell transplantation for poor prognosis Hodgkin's disease in first complete remission: a retrospective study from the Spanish GEL-TAMO cooperative group.
    Sureda A; Mataix R; Hernández-Navarro F; Jarque I; Lahuerta JJ; Tomás JF; Brunet S; Caballero D; Conde E; León A; Fernández MN; López A; Maldonado J; Bengoechea E; Callís M; Carrera D; García-Conde J; García-Laraña J; Moraleda JM; Morey M; Rifón J; Sierra J; Torres A; Domingo-Albós A
    Bone Marrow Transplant; 1997 Aug; 20(4):283-8. PubMed ID: 9285542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful allogeneic bone marrow transplantation for early relapse after autologous bone marrow transplantation in two cases of aggressive high-grade non-Hodgkin's lymphoma.
    Moreau P; Méchinaud F; Mahé B; Le Tortorec S; Rapp MJ; Maisonneuve H; Harousseau JL; Milpied N
    Bone Marrow Transplant; 1996 Sep; 18(3):665-7. PubMed ID: 8879639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
    Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F
    Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
    Bierman PJ; Sweetenham JW; Loberiza FR; Taghipour G; Lazarus HM; Rizzo JD; Schmitz N; van Besien K; Vose JM; Horowitz M; Goldstone A;
    J Clin Oncol; 2003 Oct; 21(20):3744-53. PubMed ID: 12963703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma.
    Doocey RT; Toze CL; Connors JM; Nevill TJ; Gascoyne RD; Barnett MJ; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Shepherd JD; Sutherland HJ; Voss NJ; Smith CA; Song KW
    Br J Haematol; 2005 Oct; 131(2):223-30. PubMed ID: 16197454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.
    Philip T; Armitage JO; Spitzer G; Chauvin F; Jagannath S; Cahn JY; Colombat P; Goldstone AH; Gorin NC; Flesh M
    N Engl J Med; 1987 Jun; 316(24):1493-8. PubMed ID: 3295541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allogeneic stem cell transplantation for the non-Hodgkin's lymphomas and Hodgkin's disease.
    Hale GA; Phillips GL
    Cancer Treat Rev; 2000 Dec; 26(6):411-27. PubMed ID: 11139372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
    Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.